Supplementary Figure S5: Anti-tumor activity of CD8-mIL2 in combination with anti-PD-1 in B16F10, 1956, MCA-205, and KP.mLama4 tumor models.
No takes yet. Share an insight, caveat, or question.
Moynihan et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: